Raptor Pharmaceuticals slides as Oppenheimer outlines risks

Raptor Pharmaceuticals (RPTP) falls in early trading on the heels of an Oppenheimer downgrade.

"We believe that the market is already pricing in Procysbi adoption by 80%+ patients in the US and EU at current valuation," analyst Boris Peaker says, removing his $11 price target.

Oppenheimer also says success in Huntington's (RP103) is critical for RPTP — "we view [this] as very risky," Peaker notes.

Another concern: Procysbi pricing in Europe as "reimbursement may be more challenging" than in the U.S. See: Procysbi gets EU marketing authorization.


Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs